SI-BONE, Inc. (SIBN) - Q3 2024 10-Q Summary
Business Context and Reporting Period
SI-BONE, Inc. is a medical device company focused on sacropelvic anatomy solutions, including sacroiliac joint dysfunction and pelvic trauma. This report covers the quarterly period ended September 30, 2024. The company operates as a single reportable segment, deriving the majority of its revenue from the United States (95% in Q3 2024).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $40,340 | $34,014 | $118,176 | $100,027 |
| Gross Profit | $31,903 | $26,973 | $93,344 | $80,744 |
| Gross Margin | 79% | 79% | 79% | 81% |
| Net Loss | $(6,575) | $(10,022) | $(26,418) | $(32,353) |
| Operating Cash Flow | — | — | $(13,603) | $(16,416) |
| Cash & Investments | $150.8M | — | — | — |
| Long-Term Debt | $36.2M | — | — | — |
Note: Cash and investments as of Sept 30, 2024, totaled $150.8 million ($30.2M cash + $120.6M short-term investments). Long-term debt principal outstanding is $36.7 million.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 19% year-over-year, driven primarily by a $6.0 million increase in U.S. revenue due to higher case volumes and an expanded product portfolio. International revenue grew by $0.3 million.
- Profitability: Net loss improved significantly, decreasing from $10.0 million in Q3 2023 to $6.6 million in Q3 2024. Operating loss narrowed from $11.2 million to $7.6 million.
- Expense Management: Total operating expenses increased 4% year-over-year to $39.5 million. Sales and marketing expenses rose 4% due to higher commissions and training costs. R&D expenses remained relatively flat (2% increase).
- Accounting Change: In Q1 2024, the company extended the useful life of instrument trays from three to five years, reducing depreciation expense by $1.5 million for the nine months ended September 30, 2024.
Guidance, Outlook, and Risks
- Debt Refinancing: On November 8, 2024 (post-period), the company entered a Third Amendment to its Loan and Security Agreement. This refinanced the existing $36.0 million term loan, extending the maturity to September 1, 2029, and deferring the first principal repayment to October 1, 2027 (or 2028 upon achieving a performance milestone). The revolving credit facility was terminated.
- Liquidity: Management believes existing cash and marketable securities ($150.8 million) are sufficient to fund operations for at least the next 12 months. The company has not achieved positive operating cash flow to date.
- Legal Contingency: In October 2024, the company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding an investigation under the Anti-Kickback Statute and Civil False Claims Act. The investigation concerns meals and consulting payments to healthcare professionals. The company is cooperating but cannot estimate the financial impact or duration.
- Outlook: The company continues to invest in sales force expansion and new product launches (e.g., iFuse INTRA, iFuse TORQ TNT) to drive case volume. Gross margins are expected to remain stable, though product mix changes can cause fluctuations.
Key Investor Verification Points
- DOJ Investigation Status: Monitor updates regarding the DOJ investigation into marketing practices and potential financial penalties or compliance requirements.
- Debt Covenant Compliance: Verify continued compliance with the revised financial covenants under the Third Amended Loan Agreement, specifically regarding net revenue levels.
- Cash Burn Rate: Track the rate of cash consumption given the company's continued net losses and lack of positive operating cash flow.
- Product Adoption: Assess the commercial uptake of new product lines (iFuse INTRA, iFuse TORQ TNT) and their contribution to gross margin stability.
- Inventory Levels: Review inventory growth ($25.5M as of Sept 2024 vs $20.2M prior year) to ensure it aligns with demand and does not lead to obsolescence.